Cardio Thoracic Form Module 1 Time is Up!Time is Up! 0 Hours 0 Minutes 0 Seconds 1You can check the blogs for references. : Cardio Thoracic Blogs 1. The new STS Guideline provides detailed recommendations on which three core management areas for oligometastatic NSCLC? A) Patient education, pain management, and palliative care B) Cost analysis, robotic surgery, and nutrition C) Chemotherapy regimens, radiation dose, and immunotherapy side effects D) Patient selection, staging, and integration with SBRT and systemic therapies 0 Hours 0 Minutes 0 Seconds 1You can check the blogs for references. : Cardio Thoracic Blogs 2. The review provides a three-part comparison of robotic-assisted versus conventional cardiac surgery, covering clinical outcomes and patient experience. Which topic is most likely to be the third key comparison point? A) Acquisition and running cost of the robotic platform B) Postoperative Pain Scores C) Hospital Length of Stay D) Long-term Valve Durability 0 Hours 0 Minutes 0 Seconds 1You can check the blogs for references. : Cardio Thoracic Blogs 3. For patients with complex or unstable cardiovascular disease, the guidance strongly emphasizes which kind of care model? A) Individual Physician-led Care B) Patient-only Decision Making C) Centralized Telemedicine Hub D) Team-based care 0 Hours 0 Minutes 0 Seconds 1You can check the blogs for references. : Cardio Thoracic Blogs 4. What approach does the guideline recommend for perioperative cardiac assessment to help clinicians decide if surgery should proceed or if further evaluation is needed? A) Single-stage Protocol B) Universal Stress Test Protocol C) Stepwise approach D) Binary Yes/No Checklist 0 Hours 0 Minutes 0 Seconds 1You can check the blogs for references. : Cardio Thoracic Blogs 5. Which of the following is listed as a favorable or "positive outcome" for pediatric patients on VAD support, as defined by the Pedimacs investigators? A) Placement on the waitlist for transplant B) Discharge home on inotropes C) Long-term anti-coagulation therapy D) Transition to a durable VAD
